Meglumine gadoterate induces immunoglobulin‐independent human mast cell activation via MRGPRX2
Allergy · 2023
DOI: 10.1111/all.15847 ↗Kurz gefasst
Leserbrief in der Zeitschrift Allergy, 2023. Verfasst von Paula H Ruiz de Azcárate und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autónoma de Madrid (…. Hauptthemen laut MEDLINE: Meglumine, Organometallic Compounds. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundación de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC), Instituto de Salud Carlos III.
Abstract (Originalsprache)
Meglumine gadoterate induces immunoglobulin-independent human mast cell activation via MRGPRX2To the Editor, Gadolinium-based contrast agents (GBCA) are intravenous drugs used to enhance resolution in magnetic resonance imaging.They can induce immediate hypersensitivity reactions, yet their pathogenic mechanisms remain poorly characterized.This hampers the ability to predict which patients are at risk of developing them. 1 In fact, affected patients usually show negative skin tests and can react upon the first known GBCA exposure, which implies that IgE-independent mechanisms might be driving this inflammatory response.The Mas-related G protein-coupled receptor member X2 (MRGPRX2) has been recently associated with non-IgE-mediated immediate hypersensitivity reactions.2 Some drugs, such as fluoroquinolones, vancomycin, neuromuscular-blocking agents, icatibant, morphine, leuprolide, and iodinated contrast media, have been reported to activate MRGPRX2, which is highly expressed in mast cells (MCs).3To assess the ability of GBCA to induce non-IgE-mediated hypersensitivity reactions, we stimulated the human MC line LAD2
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
- Department of Allergy, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
- Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid, Spain.
- Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.
- Department of Medicine, McMaster Immunology Research Centre (MIRC), Schroeder Allergy and Immunology Research Institute (SAIRI), McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Paula H Ruiz de Azcárate, Celia López-Sanz, Francisco Vega, Rodrigo Jiménez-Saiz
Förderung
- Fundación de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC)
- Instituto de Salud Carlos III
Zitieren
APA
Ruiz de Azcárate, P. H., López-Sanz, C., López-Raigada, A., Vega, F., Jiménez-Saiz, R., & Blanco, C. (2023). Meglumine gadoterate induces immunoglobulin‐independent human mast cell activation via MRGPRX2. Allergy. https://doi.org/10.1111/all.15847
Vancouver
Ruiz de Azcárate PH, López-Sanz C, López-Raigada A, Vega F, Jiménez-Saiz R, Blanco C. Meglumine gadoterate induces immunoglobulin‐independent human mast cell activation via MRGPRX2. Allergy. 2023. doi:10.1111/all.15847
BibTeX
@article{RuizdeAzcrate2023,
author = {Ruiz de Azcárate, Paula H and López-Sanz, Celia and López-Raigada, Azahara and Vega, Francisco and Jiménez-Saiz, Rodrigo and Blanco, Carlos},
title = {Meglumine gadoterate induces immunoglobulin‐independent human mast cell activation via MRGPRX2},
journal = {Allergy},
year = {2023},
doi = {10.1111/all.15847}
}
EUVIMED